APO Research
Talk to an analyst

APO RESEARCH · REPORT

Transdermal Scopolamine

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Transdermal Scopolamine Industry Growth and Trends Forecast to 2032

20 December 202599 pages

Choose your research edition.

Industry ResearchTransdermal Scopolamine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Transdermal Scopolamine Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Transdermal Scopolamine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Transdermal Scopolamine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Transdermal Scopolamine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Transdermal Scopolamine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Transdermal Scopolamine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Transdermal Scopolamine is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Transdermal Scopolamine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Transdermal Scopolamine include Novartis AG, Pfizer, GlaxoSmithKline plc, Baxter International Inc., Perrigo Company plc., Nichi-Iko, Myungmoon Pharma Co. LTD. and Caleb Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Transdermal Scopolamine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Transdermal Scopolamine market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Transdermal Scopolamine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Transdermal Scopolamine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Transdermal Scopolamine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Transdermal Scopolamine Market by Company

Novartis AG

Pfizer

GlaxoSmithKline plc

Baxter International Inc.

Perrigo Company plc.

Nichi-Iko

Myungmoon Pharma Co. LTD.

Caleb Pharmaceuticals, Inc.

Transdermal Scopolamine Segment by Type

Injections Type

Syrups Type

Tablet Type

Gel Type

Patch Type

Transdermal Scopolamine Segment by Application

Cough

Asthma

Parkinson's Disease

Narcotic Analgesia

Motion Sickness

Others

Transdermal Scopolamine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Scopolamine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Transdermal Scopolamine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Scopolamine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Transdermal Scopolamine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Transdermal Scopolamine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Injections Type Table 2. Major Company of Syrups Type Table 3. Major Company of Tablet Type Table 4. Major Company of Gel Type Table 5. Major Company of Patch Type Table 6. Global Transdermal Scopolamine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Transdermal Scopolamine Sales by Type (2021-2026) & (k units) Table 8. Global Transdermal Scopolamine Sales Market Share in Volume by Type (2021-2026) Table 9. Global Transdermal Scopolamine Sales by Type (2021-2026) & (US$ Million) Table 10. Global Transdermal Scopolamine Sales Market Share in Value by Type (2021-2026) Table 11. Global Transdermal Scopolamine Price by Type (2021-2026) & (US$/unit) Table 12. Global Transdermal Scopolamine Sales by Type (2027-2032) & (k units) Table 13. Global Transdermal Scopolamine Sales Market Share in Volume by Type (2027-2032) Table 14. Global Transdermal Scopolamine Sales by Type (2027-2032) & (US$ Million) Table 15. Global Transdermal Scopolamine Sales Market Share in Value by Type (2027-2032) Table 16. Global Transdermal Scopolamine Price by Type (2027-2032) & (US$/unit) Table 17. North America Transdermal Scopolamine Sales by Type (2021-2026) & (k units) Table 18. North America Transdermal Scopolamine Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Transdermal Scopolamine Sales by Type (2021-2026) & (k units) Table 20. Europe Transdermal Scopolamine Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Transdermal Scopolamine Sales by Type (2021-2026) & (k units) Table 22. Asia-Pacific Transdermal Scopolamine Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Transdermal Scopolamine Sales by Type (2021-2026) & (k units) Table 24. Latin America Transdermal Scopolamine Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Transdermal Scopolamine Sales by Type (2021-2026) & (k units) Table 26. Middle East and Africa Transdermal Scopolamine Sales by Type (2021-2026) & (US$ Million) Table 27. Transdermal Scopolamine Industry Trends Table 28. Transdermal Scopolamine Industry Drivers Table 29. Transdermal Scopolamine Industry Opportunities and Challenges Table 30. Transdermal Scopolamine Industry Restraints Table 31. Global Transdermal Scopolamine Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Transdermal Scopolamine Revenue Market Share by Company (2021-2026) Table 33. Global Transdermal Scopolamine Sales by Company (2021-2026) & (k units) Table 34. Global Transdermal Scopolamine Sales Share by Company (2021-2026) Table 35. Global Transdermal Scopolamine Market Price by Company (2021-2026) & (US$/unit) Table 36. Global Transdermal Scopolamine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Transdermal Scopolamine Major Company Production Sites and Headquarters Table 38. Global Transdermal Scopolamine Company, Product Type & Application Table 39. Global Transdermal Scopolamine Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Transdermal Scopolamine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Transdermal Scopolamine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Transdermal Scopolamine Sales by Region (2021-2026) & (k units) Table 44. Global Transdermal Scopolamine Sales Market Share in Volume by Region (2021-2026) Table 45. Global Transdermal Scopolamine Sales by Region (2021-2026) & (US$ Million) Table 46. Global Transdermal Scopolamine Sales Market Share in Value by Region (2021-2026) Table 47. Global Transdermal Scopolamine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 48. Global Transdermal Scopolamine Sales by Region (2027-2032) & (k units) Table 49. Global Transdermal Scopolamine Sales Market Share in Volume by Region (2027-2032) Table 50. Global Transdermal Scopolamine Sales by Region (2027-2032) & (US$ Million) Table 51. Global Transdermal Scopolamine Sales Market Share in Value by Region (2027-2032) Table 52. Global Transdermal Scopolamine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 53. Global Transdermal Scopolamine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Transdermal Scopolamine Sales by Application (2021-2026) & (k units) Table 55. Global Transdermal Scopolamine Sales Market Share in Volume by Application (2021-2026) Table 56. Global Transdermal Scopolamine Sales by Application (2021-2026) & (US$ Million) Table 57. Global Transdermal Scopolamine Sales Market Share in Value by Application (2021-2026) Table 58. Global Transdermal Scopolamine Price by Application (2021-2026) & (US$/unit) Table 59. Global Transdermal Scopolamine Sales by Application (2027-2032) & (k units) Table 60. Global Transdermal Scopolamine Sales Market Share in Volume by Application (2027-2032) Table 61. Global Transdermal Scopolamine Sales by Application (2027-2032) & (US$ Million) Table 62. Global Transdermal Scopolamine Sales Market Share in Value by Application (2027-2032) Table 63. Global Transdermal Scopolamine Price by Application (2027-2032) & (US$/unit) Table 64. North America Transdermal Scopolamine Sales by Application (2021-2026) & (k units) Table 65. North America Transdermal Scopolamine Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Transdermal Scopolamine Sales by Application (2021-2026) & (k units) Table 67. Europe Transdermal Scopolamine Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Transdermal Scopolamine Sales by Application (2021-2026) & (k units) Table 69. Asia-Pacific Transdermal Scopolamine Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Transdermal Scopolamine Sales by Application (2021-2026) & (k units) Table 71. Latin America Transdermal Scopolamine Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Transdermal Scopolamine Sales by Application (2021-2026) & (k units) Table 73. Middle East and Africa Transdermal Scopolamine Sales by Application (2021-2026) & (US$ Million) Table 74. Novartis AG Company Information Table 75. Novartis AG Business Overview Table 76. Novartis AG Transdermal Scopolamine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Novartis AG Transdermal Scopolamine Product Portfolio Table 78. Novartis AG Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Transdermal Scopolamine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Pfizer Transdermal Scopolamine Product Portfolio Table 83. Pfizer Recent Development Table 84. GlaxoSmithKline plc Company Information Table 85. GlaxoSmithKline plc Business Overview Table 86. GlaxoSmithKline plc Transdermal Scopolamine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline plc Transdermal Scopolamine Product Portfolio Table 88. GlaxoSmithKline plc Recent Development Table 89. Baxter International Inc. Company Information Table 90. Baxter International Inc. Business Overview Table 91. Baxter International Inc. Transdermal Scopolamine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Baxter International Inc. Transdermal Scopolamine Product Portfolio Table 93. Baxter International Inc. Recent Development Table 94. Perrigo Company plc. Company Information Table 95. Perrigo Company plc. Business Overview Table 96. Perrigo Company plc. Transdermal Scopolamine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Perrigo Company plc. Transdermal Scopolamine Product Portfolio Table 98. Perrigo Company plc. Recent Development Table 99. Nichi-Iko Company Information Table 100. Nichi-Iko Business Overview Table 101. Nichi-Iko Transdermal Scopolamine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Nichi-Iko Transdermal Scopolamine Product Portfolio Table 103. Nichi-Iko Recent Development Table 104. Myungmoon Pharma Co. LTD. Company Information Table 105. Myungmoon Pharma Co. LTD. Business Overview Table 106. Myungmoon Pharma Co. LTD. Transdermal Scopolamine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Myungmoon Pharma Co. LTD. Transdermal Scopolamine Product Portfolio Table 108. Myungmoon Pharma Co. LTD. Recent Development Table 109. Caleb Pharmaceuticals, Inc. Company Information Table 110. Caleb Pharmaceuticals, Inc. Business Overview Table 111. Caleb Pharmaceuticals, Inc. Transdermal Scopolamine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Caleb Pharmaceuticals, Inc. Transdermal Scopolamine Product Portfolio Table 113. Caleb Pharmaceuticals, Inc. Recent Development Table 114. North America Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 115. North America Transdermal Scopolamine Sales by Country (2021-2026) & (k units) Table 116. North America Transdermal Scopolamine Sales Market Share by Country (2021-2026) Table 117. North America Transdermal Scopolamine Sales Forecast by Country (2027-2032) & (k units) Table 118. North America Transdermal Scopolamine Sales Market Share Forecast by Country (2027-2032) Table 119. North America Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 120. North America Transdermal Scopolamine Market Size by Country (2021-2026) & (US$ Million) Table 121. North America Transdermal Scopolamine Market Share by Country (2021-2026) Table 122. North America Transdermal Scopolamine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 123. North America Transdermal Scopolamine Market Share Forecast by Country (2027-2032) Table 124. Europe Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 125. Europe Transdermal Scopolamine Sales by Country (2021-2026) & (k units) Table 126. Europe Transdermal Scopolamine Sales Market Share by Country (2021-2026) Table 127. Europe Transdermal Scopolamine Sales Forecast by Country (2027-2032) & (k units) Table 128. Europe Transdermal Scopolamine Sales Market Share Forecast by Country (2027-2032) Table 129. Europe Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 130. Europe Transdermal Scopolamine Market Size by Country (2021-2026) & (US$ Million) Table 131. Europe Transdermal Scopolamine Market Share by Country (2021-2026) Table 132. Europe Transdermal Scopolamine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 133. Europe Transdermal Scopolamine Market Share Forecast by Country (2027-2032) Table 134. Asia-Pacific Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 135. Asia-Pacific Transdermal Scopolamine Sales by Country (2021-2026) & (k units) Table 136. Asia-Pacific Transdermal Scopolamine Sales Market Share by Country (2021-2026) Table 137. Asia-Pacific Transdermal Scopolamine Sales Forecast by Country (2027-2032) & (k units) Table 138. Asia-Pacific Transdermal Scopolamine Sales Market Share Forecast by Country (2027-2032) Table 139. Asia-Pacific Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 140. Asia-Pacific Transdermal Scopolamine Market Size by Country (2021-2026) & (US$ Million) Table 141. Asia-Pacific Transdermal Scopolamine Market Share by Country (2021-2026) Table 142. Asia-Pacific Transdermal Scopolamine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 143. Asia-Pacific Transdermal Scopolamine Market Share Forecast by Country (2027-2032) Table 144. Latin America Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 145. Latin America Transdermal Scopolamine Sales by Country (2021-2026) & (k units) Table 146. Latin America Transdermal Scopolamine Sales Market Share by Country (2021-2026) Table 147. Latin America Transdermal Scopolamine Sales Forecast by Country (2027-2032) & (k units) Table 148. Latin America Transdermal Scopolamine Sales Market Share Forecast by Country (2027-2032) Table 149. Latin America Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. Latin America Transdermal Scopolamine Market Size by Country (2021-2026) & (US$ Million) Table 151. Latin America Transdermal Scopolamine Market Share by Country (2021-2026) Table 152. Latin America Transdermal Scopolamine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. Latin America Transdermal Scopolamine Market Share Forecast by Country (2027-2032) Table 154. Middle East and Africa Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 155. Middle East and Africa Transdermal Scopolamine Sales by Country (2021-2026) & (k units) Table 156. Middle East and Africa Transdermal Scopolamine Sales Market Share by Country (2021-2026) Table 157. Middle East and Africa Transdermal Scopolamine Sales Forecast by Country (2027-2032) & (k units) Table 158. Middle East and Africa Transdermal Scopolamine Sales Market Share Forecast by Country (2027-2032) Table 159. Middle East and Africa Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Middle East and Africa Transdermal Scopolamine Market Size by Country (2021-2026) & (US$ Million) Table 161. Middle East and Africa Transdermal Scopolamine Market Share by Country (2021-2026) Table 162. Middle East and Africa Transdermal Scopolamine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Middle East and Africa Transdermal Scopolamine Market Share Forecast by Country (2027-2032) Table 164. Key Raw Materials Table 165. Raw Materials Key Suppliers Table 166. Transdermal Scopolamine Distributors List Table 167. Transdermal Scopolamine Customers List Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Transdermal Scopolamine Image Figure 2. Global Transdermal Scopolamine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Transdermal Scopolamine Market Size (2021-2032) & (US$ Million) Figure 4. Global Transdermal Scopolamine Sales (2021-2032) & (k units) Figure 5. Injections Type Image Figure 6. Global Injections Type Sales YoY Growth (2021-2032) & (k units) Figure 7. Syrups Type Image Figure 8. Global Syrups Type Sales YoY Growth (2021-2032) & (k units) Figure 9. Tablet Type Image Figure 10. Global Tablet Type Sales YoY Growth (2021-2032) & (k units) Figure 11. Gel Type Image Figure 12. Global Gel Type Sales YoY Growth (2021-2032) & (k units) Figure 13. Patch Type Image Figure 14. Global Patch Type Sales YoY Growth (2021-2032) & (k units) Figure 15. Global Transdermal Scopolamine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Transdermal Scopolamine Market Share by Type 2025 VS 2032 Figure 17. North America Transdermal Scopolamine Sales Market Share in Volume by Type in 2025 Figure 18. North America Transdermal Scopolamine Sales Market Share in Value by Type in 2025 Figure 19. Europe Transdermal Scopolamine Sales Market Share in Volume by Type in 2025 Figure 20. Europe Transdermal Scopolamine Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Transdermal Scopolamine Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Transdermal Scopolamine Sales Market Share in Value by Type in 2025 Figure 23. Latin America Transdermal Scopolamine Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Transdermal Scopolamine Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Transdermal Scopolamine Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Transdermal Scopolamine Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Transdermal Scopolamine Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Cough Image Figure 30. Global Cough Sales YoY Growth (2021-2032) & (k units) Figure 31. Asthma Image Figure 32. Global Asthma Sales YoY Growth (2021-2032) & (k units) Figure 33. Parkinson's Disease Image Figure 34. Global Parkinson's Disease Sales YoY Growth (2021-2032) & (k units) Figure 35. Narcotic Analgesia Image Figure 36. Global Narcotic Analgesia Sales YoY Growth (2021-2032) & (k units) Figure 37. Motion Sickness Image Figure 38. Global Motion Sickness Sales YoY Growth (2021-2032) & (k units) Figure 39. Others Image Figure 40. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 41. Global Transdermal Scopolamine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 42. Global Transdermal Scopolamine Market Share by Application 2025 VS 2032 Figure 43. North America Transdermal Scopolamine Sales Market Share in Volume by Application in 2025 Figure 44. North America Transdermal Scopolamine Sales Market Share in Value by Application in 2025 Figure 45. Europe Transdermal Scopolamine Sales Market Share in Volume by Application in 2025 Figure 46. Europe Transdermal Scopolamine Sales Market Share in Value by Application in 2025 Figure 47. Asia-Pacific Transdermal Scopolamine Sales Market Share in Volume by Application in 2025 Figure 48. Asia-Pacific Transdermal Scopolamine Sales Market Share in Value by Application in 2025 Figure 49. Latin America Transdermal Scopolamine Sales Market Share in Volume by Application in 2025 Figure 50. Latin America Transdermal Scopolamine Sales Market Share in Value by Application in 2025 Figure 51. Middle East and Africa Transdermal Scopolamine Sales Market Share in Volume by Application in 2025 Figure 52. Middle East and Africa Transdermal Scopolamine Sales Market Share in Value by Application in 2025 Figure 53. North America Transdermal Scopolamine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. North America Transdermal Scopolamine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. North America Transdermal Scopolamine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. North America Transdermal Scopolamine Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Transdermal Scopolamine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Europe Transdermal Scopolamine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Transdermal Scopolamine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Europe Transdermal Scopolamine Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Transdermal Scopolamine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 62. Asia-Pacific Transdermal Scopolamine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Transdermal Scopolamine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Asia-Pacific Transdermal Scopolamine Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Transdermal Scopolamine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 66. Latin America Transdermal Scopolamine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America Transdermal Scopolamine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Latin America Transdermal Scopolamine Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Transdermal Scopolamine Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 70. Middle East and Africa Transdermal Scopolamine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa Transdermal Scopolamine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 72. Middle East and Africa Transdermal Scopolamine Market Share by Country: 2021 VS 2025 VS 2032 Figure 73. Transdermal Scopolamine Value Chain Figure 74. Key Raw Materials Price Figure 75. Manufacturing Cost Structure Figure 76. Transdermal Scopolamine Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Years Considered Figure 80. Research Process Figure 81. Key Executives Interviewed

Scope & coverage.

Types
  • Injections Type
  • Syrups Type
  • Tablet Type
  • Gel Type
  • Patch Type
Applications
  • Cough
  • Asthma
  • Parkinson's Disease
  • Narcotic Analgesia
  • Motion Sickness
  • Others
Companies covered
  • Novartis AG
  • Pfizer
  • GlaxoSmithKline plc
  • Baxter International Inc.
  • Perrigo Company plc.
  • Nichi-Iko
  • Myungmoon Pharma Co. LTD.
  • Caleb Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Transdermal Scopolamine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Transdermal Scopolamine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Transdermal Scopolamine Market by Type
  6. 1.3.1 Injections Type
  7. 1.3.2 Syrups Type
  8. 1.3.3 Tablet Type
  9. 1.3.4 Gel Type
  10. 1.3.5 Patch Type
  11. 1.4 Global Transdermal Scopolamine Market Size by Type
  12. 1.4.1 Global Transdermal Scopolamine Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Transdermal Scopolamine Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Transdermal Scopolamine Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Transdermal Scopolamine Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Transdermal Scopolamine Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Transdermal Scopolamine Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Transdermal Scopolamine Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Transdermal Scopolamine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Transdermal Scopolamine Industry Trends
  2. 2.2 Transdermal Scopolamine Industry Drivers
  3. 2.3 Transdermal Scopolamine Industry Opportunities and Challenges
  4. 2.4 Transdermal Scopolamine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Transdermal Scopolamine Revenue (2021-2026)
  2. 3.2 Global Top Players by Transdermal Scopolamine Sales (2021-2026)
  3. 3.3 Global Top Players by Transdermal Scopolamine Price (2021-2026)
  4. 3.4 Global Transdermal Scopolamine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Transdermal Scopolamine Major Company Production Sites & Headquarters
  6. 3.6 Global Transdermal Scopolamine Company, Product Type & Application
  7. 3.7 Global Transdermal Scopolamine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Transdermal Scopolamine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Transdermal Scopolamine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Transdermal Scopolamine Tier 1, Tier 2, and Tier 3
4 Transdermal Scopolamine Regional Status and Outlook
  1. 4.1 Global Transdermal Scopolamine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Transdermal Scopolamine Historic Market Size by Region
  3. 4.2.1 Global Transdermal Scopolamine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Transdermal Scopolamine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Transdermal Scopolamine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Transdermal Scopolamine Forecasted Market Size by Region
  7. 4.3.1 Global Transdermal Scopolamine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Transdermal Scopolamine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Transdermal Scopolamine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Transdermal Scopolamine by Application
  1. 5.1 Transdermal Scopolamine Market by Application
  2. 5.1.1 Cough
  3. 5.1.2 Asthma
  4. 5.1.3 Parkinson's Disease
  5. 5.1.4 Narcotic Analgesia
  6. 5.1.5 Motion Sickness
  7. 5.1.6 Others
  8. 5.2 Global Transdermal Scopolamine Market Size by Application
  9. 5.2.1 Global Transdermal Scopolamine Market Size Overview by Application (2021-2032)
  10. 5.2.2 Global Transdermal Scopolamine Historic Market Size Review by Application (2021-2026)
  11. 5.2.3 Global Transdermal Scopolamine Forecasted Market Size by Application (2027-2032)
  12. 5.3 Key Regions Market Size by Application
  13. 5.3.1 North America Transdermal Scopolamine Sales Breakdown by Application (2021-2026)
  14. 5.3.2 Europe Transdermal Scopolamine Sales Breakdown by Application (2021-2026)
  15. 5.3.3 Asia-Pacific Transdermal Scopolamine Sales Breakdown by Application (2021-2026)
  16. 5.3.4 South America Transdermal Scopolamine Sales Breakdown by Application (2021-2026)
  17. 5.3.5 Middle East and Africa Transdermal Scopolamine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis AG
  2. 6.1.1 Novartis AG Company Information
  3. 6.1.2 Novartis AG Business Overview
  4. 6.1.3 Novartis AG Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis AG Transdermal Scopolamine Product Portfolio
  6. 6.1.5 Novartis AG Recent Developments
  7. 6.2 Pfizer
  8. 6.2.1 Pfizer Company Information
  9. 6.2.2 Pfizer Business Overview
  10. 6.2.3 Pfizer Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer Transdermal Scopolamine Product Portfolio
  12. 6.2.5 Pfizer Recent Developments
  13. 6.3 GlaxoSmithKline plc
  14. 6.3.1 GlaxoSmithKline plc Company Information
  15. 6.3.2 GlaxoSmithKline plc Business Overview
  16. 6.3.3 GlaxoSmithKline plc Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 GlaxoSmithKline plc Transdermal Scopolamine Product Portfolio
  18. 6.3.5 GlaxoSmithKline plc Recent Developments
  19. 6.4 Baxter International Inc.
  20. 6.4.1 Baxter International Inc. Company Information
  21. 6.4.2 Baxter International Inc. Business Overview
  22. 6.4.3 Baxter International Inc. Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Baxter International Inc. Transdermal Scopolamine Product Portfolio
  24. 6.4.5 Baxter International Inc. Recent Developments
  25. 6.5 Perrigo Company plc.
  26. 6.5.1 Perrigo Company plc. Company Information
  27. 6.5.2 Perrigo Company plc. Business Overview
  28. 6.5.3 Perrigo Company plc. Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Perrigo Company plc. Transdermal Scopolamine Product Portfolio
  30. 6.5.5 Perrigo Company plc. Recent Developments
  31. 6.6 Nichi-Iko
  32. 6.6.1 Nichi-Iko Company Information
  33. 6.6.2 Nichi-Iko Business Overview
  34. 6.6.3 Nichi-Iko Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Nichi-Iko Transdermal Scopolamine Product Portfolio
  36. 6.6.5 Nichi-Iko Recent Developments
  37. 6.7 Myungmoon Pharma Co. LTD.
  38. 6.7.1 Myungmoon Pharma Co. LTD. Company Information
  39. 6.7.2 Myungmoon Pharma Co. LTD. Business Overview
  40. 6.7.3 Myungmoon Pharma Co. LTD. Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Myungmoon Pharma Co. LTD. Transdermal Scopolamine Product Portfolio
  42. 6.7.5 Myungmoon Pharma Co. LTD. Recent Developments
  43. 6.8 Caleb Pharmaceuticals, Inc.
  44. 6.8.1 Caleb Pharmaceuticals, Inc. Company Information
  45. 6.8.2 Caleb Pharmaceuticals, Inc. Business Overview
  46. 6.8.3 Caleb Pharmaceuticals, Inc. Transdermal Scopolamine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Caleb Pharmaceuticals, Inc. Transdermal Scopolamine Product Portfolio
  48. 6.8.5 Caleb Pharmaceuticals, Inc. Recent Developments
7 North America by Country
  1. 7.1 North America Transdermal Scopolamine Sales by Country
  2. 7.1.1 North America Transdermal Scopolamine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Transdermal Scopolamine Sales by Country (2021-2026)
  4. 7.1.3 North America Transdermal Scopolamine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Transdermal Scopolamine Market Size by Country
  6. 7.2.1 North America Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Transdermal Scopolamine Market Size by Country (2021-2026)
  8. 7.2.3 North America Transdermal Scopolamine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Transdermal Scopolamine Sales by Country
  2. 8.1.1 Europe Transdermal Scopolamine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Transdermal Scopolamine Sales by Country (2021-2026)
  4. 8.1.3 Europe Transdermal Scopolamine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Transdermal Scopolamine Market Size by Country
  6. 8.2.1 Europe Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Transdermal Scopolamine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Transdermal Scopolamine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Transdermal Scopolamine Sales by Country
  2. 9.1.1 Asia-Pacific Transdermal Scopolamine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Transdermal Scopolamine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Transdermal Scopolamine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Transdermal Scopolamine Market Size by Country
  6. 9.2.1 Asia-Pacific Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Transdermal Scopolamine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Transdermal Scopolamine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Transdermal Scopolamine Sales by Country
  2. 10.1.1 South America Transdermal Scopolamine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Transdermal Scopolamine Sales by Country (2021-2026)
  4. 10.1.3 South America Transdermal Scopolamine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Transdermal Scopolamine Market Size by Country
  6. 10.2.1 South America Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Transdermal Scopolamine Market Size by Country (2021-2026)
  8. 10.2.3 South America Transdermal Scopolamine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Transdermal Scopolamine Sales by Country
  2. 11.1.1 Middle East and Africa Transdermal Scopolamine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Transdermal Scopolamine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Transdermal Scopolamine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Transdermal Scopolamine Market Size by Country
  6. 11.2.1 Middle East and Africa Transdermal Scopolamine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Transdermal Scopolamine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Transdermal Scopolamine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Transdermal Scopolamine Value Chain Analysis
  2. 12.1.1 Transdermal Scopolamine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Transdermal Scopolamine Production Mode & Process
  7. 12.2 Transdermal Scopolamine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Transdermal Scopolamine Distributors
  10. 12.2.3 Transdermal Scopolamine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst